Cell Therapies for Atrophic AMD

Related

• 

  Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes

  Carl D. Regillo, MD

  Annual Meeting Talks

  2022

• 

  Safety of Intravitreal Pegcetacoplan in Geographic Atrophy: Results from the Phase 3 DERBY and OAKS Trials

  David S. Boyer, MD

  Updates from the Field

  2021

• 

  Expert Panel: Pegcetacoplan Safety

  Andre J. Witkin, MD

  David A. Eichenbaum, MD, FASRS

  Samuel Anthony Minaker, MD, MSc

  Janani Singaravelu, MS, MD

  Sunir J. Garg, MD, FACS, FASRS

  Annual Meeting Talks

  2024